Based on the Fate Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Fate Therapeutics Inc is not available over the next 12 months. Fate Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Fate Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Fate Therapeutics Inc’s stock price was EUR 0.95. Fate Therapeutics Inc’s stock price has changed by -8.38% over the past week, -28.69% over the past month and -86.92% over the last year.
No recent analyst target price found for Fate Therapeutics Inc
No recent average analyst rating found for Fate Therapeutics Inc
Company Overview Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Read Less
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple mye...Read More
Frequently Asked Questions About Fate Therapeutics Inc (F6T:F) Stock
Stock Target Advisor's fundamental analysis for Fate Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on F6T:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on F6T:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on F6T:F's stock to indicate if its overvalued.
The last closing price of F6T:F's stock was EUR 0.95.
The most recent market capitalization for F6T:F is EUR 0.15B.
Unfortunately we do not have enough analyst data on F6T:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fate Therapeutics Inc's stock.
As per our most recent records Fate Therapeutics Inc has 181 Employees.
Fate Therapeutics Inc's registered address is 12278 Scripps Summit Drive, San Diego, CA, United States, 92131.
You can get more information about it from Fate Therapeutics Inc's website at https://www.fatetherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Fate Therapeutics Inc (F6T:F) Stock
Stock Target Advisor's fundamental analysis for Fate Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on F6T:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on F6T:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on F6T:F's stock to indicate if its overvalued.
The last closing price of F6T:F's stock was EUR 0.95.
The most recent market capitalization for F6T:F is EUR 0.15B.
Unfortunately we do not have enough analyst data on F6T:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fate Therapeutics Inc's stock.
As per our most recent records Fate Therapeutics Inc has 181 Employees.
Fate Therapeutics Inc's registered address is 12278 Scripps Summit Drive, San Diego, CA, United States, 92131.
You can get more information about it from Fate Therapeutics Inc's website at https://www.fatetherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for F6T:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
